A Phase 2 clinical study to assess efficacy of Induction ipilimumab/nivolumab to spare the Bladder in urothelial bladder cancer (Indi-Blade)
Latest Information Update: 20 Mar 2024
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Capecitabine; Fluorouracil; Mitomycin
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms Indi-Blade
- 15 Mar 2024 Planned End Date changed from 1 Dec 2027 to 5 Sep 2027.
- 15 Mar 2024 Planned primary completion date changed from 1 Sep 2024 to 5 Sep 2025.
- 15 Mar 2024 Status changed from recruiting to active, no longer recruiting.